Asthma Among Hospitalized Patients with COVID-19 and Related Outcomes

Lovinsky‐Desir, Stephanie; Deshpande, Deepti; De, Aliva; Murray, Laurie; Stingone, Jeanette A.; Chan, Angela; Patel, Neha; Rai, Nooralam; DiMango, Emily; Milner, Joshua D.; Kattan, Meyer

doi:10.2139/ssrn.3616172

Cited by 24 publications

(36 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several risk factors for poor outcome of COVID-19 have been identified, including older age, diabetes, cardiovascular disease and obesity [ [3] , [4] , [5] ]. Since the outbreak there has been much debate about the extent to which asthma is a risk factor for susceptibility to SARS-CoV-2 infection or severe disease progression of COVID-19, and results of studies addressing these issues vary substantially [ [6] , [7] , [8] , [9] , [10] , [11] , [12] ]. Recent large studies and meta-analyses however suggest that asthma patients in general may not be at risk for severe COVID-19, which may be due to a potential protective effect of type 2 inflammation [ [13] , [14] , [15] , [16] , [17] ].…”

Section: Introductionmentioning

confidence: 99%

Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy

Eger¹,

Hashimoto²,

Braunstahl³

et al. 2021

Respiratory Medicine

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy

Eger¹,

Hashimoto²,

Braunstahl³

et al. 2021

Respiratory Medicine

View full text Add to dashboard Cite

“…However, recently, it has been reported that, overall, it may not be associated with severe disease or mortality. 71 A possible explanation is that, although asthma predisposes to respiratory distress, ACE2 is down-regulated in asthma and other respiratory allergies, and therefore patients are less susceptible to infection by SARS-CoV-2. 72 Given the fact that ACE2 down-regulation is considered to be an important factor attributed to complications in later course of the disease, it could be assumed that asthmatic patients should be at increased risk for a poor prognosis.…”

Section: Ob E S It Y and A S Thma A S E X Ample S Of Cond Iti On S mentioning

confidence: 99%

ACE2 in the second act of COVID‐19 syndrome: Peptide dysregulation and possible correction with oestrogen

Zhang

Zetter

Guerra

et al. 2021

J Neuroendocrinology

View full text Add to dashboard Cite

The renin-angiotensin-aldosterone system (RAAS) comprises an endocrine cascade of vasoactive peptides to mineralocorticoids that orchestrate key processes in mammalian physiology. Notably, it preserves end-organ perfusion by regulating extracellular volume, sodium and water balance, and cardiovascular activity. The RAAS is also crucially involved in the inflammatory response, epithelial cell proliferation, angiogenesis and fibrosis. Two zinc metalloproteases are pivotal players in the RAAS, namely angiotensin-converting

show abstract

“…For example, it may be observed that patients with preexisting Type 2 inflammatory conditions are more susceptible to the initial stages of viral replication due to blunted anti-viral type 1 immunity, but may be relatively protected from later excessive inflammatory complications of COVID-19 such as severe ARDS. Importantly, recent studies found that asthma does not appear to be a significant comorbidity for patients hospitalized with severe COVID-19, and asthma does not increase risk for mechanical ventilation [140,141]. It would be interested to see how individuals with Th2-dominated parasitic infections like schistosomiasis [142,143] respond following SARS-CoV-2 infection.…”

Section: Balancing Type 1 and Type 2 Immunity In Covid-19mentioning

confidence: 99%

Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19

et al. 2020

View full text Add to dashboard Cite

Severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) gains entry into the lung epithelial cells by binding to the surface protein angiotensin-converting enzyme 2. Severe SARS-CoV-2 infection, also known as coronavirus disease 2019 (COVID-19), can lead to death due to acute respiratory distress syndrome mediated by inflammatory immune cells and cytokines. In this review, we discuss the molecular and biochemical bases of the interaction between SARS-CoV-2 and human cells, and in doing so we highlight knowledge gaps currently precluding development of new effective therapies. In particular, discovery of novel treatment targets in COVID-19 will start from understanding pathologic changes based on a large number of autopsy lung tissue samples. Pathogenetic roles of potential molecular targets identified in human lung tissues must be validated in established animal models. Overall, this stepwise approach will enable appropriate selection of candidate therapeutic modalities targeting SARS-CoV2 and the host inflammatory response.

show abstract

Asthma Among Hospitalized Patients with COVID-19 and Related Outcomes

Cited by 24 publications

References 0 publications

Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy

Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy

ACE2 in the second act of COVID‐19 syndrome: Peptide dysregulation and possible correction with oestrogen

Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19

Contact Info

Product

Resources

About